Kenvue Inc. (NYSE:KVUE) Stock Has Consensus Target Price of $19.00

Key Points

• Analysts remain cautious on Kenvue: Ten of 12 analysts rate the stock “Hold,” while two recommend buying it. The average 12-month price target is $19.00, modestly above its reported opening price of $17.39.
• Kenvue’s latest quarterly results slightly missed expectations, with earnings per share of $0.31 versus $0.32 expected and revenue of $3.96 billion versus $3.97 billion forecast. Revenue nevertheless increased 3% year over year.
• The company pays a quarterly dividend of $0.21, equivalent to an annualized $0.84 and a 4.8% yield; its dividend payout ratio is high at 96.55%.

Kenvue Inc. (NYSE:KVUE - Get Free Report) has been assigned an average recommendation of "Hold" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $19.00.

A number of analysts recently issued reports on the stock. Barclays increased their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Kenvue in a research report on Friday, September 11th. Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of Kenvue from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, UBS Group cut their target price on shares of Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th.

Kenvue Price Performance

KVUE stock opened at $17.39 on Tuesday. The company has a market cap of $33.39 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 1.58 and a beta of 0.48. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $18.58 and a two-hundred day moving average price of $18.17. Kenvue has a 12-month low of $14.02 and a 12-month high of $20.13.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to analysts' expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business's revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.29 earnings per share. As a group, research analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were given a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a yield of 4.8%. Kenvue's dividend payout ratio (DPR) is 96.55%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Johnson Financial Group Inc. purchased a new position in Kenvue in the 2nd quarter worth approximately $26,000. MV Capital Management Inc. acquired a new position in Kenvue in the 4th quarter worth $28,000. CoreCap Advisors LLC lifted its holdings in Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after buying an additional 591 shares in the last quarter. Reflection Asset Management purchased a new position in Kenvue in the 4th quarter valued at about $32,000. Finally, Bell Investment Advisors Inc purchased a new position in Kenvue in the 2nd quarter valued at about $35,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc NYSE: KVUE is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue's principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson's and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson's consumer health business and became an independent publicly traded company in 2023.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.